| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SRT Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide.
Sartorius Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €326.50 |
| 52 Week High | €834.00 |
| 52 Week Low | €276.50 |
| Beta | 0.40 |
| 1 Month Change | -5.09% |
| 3 Month Change | -6.18% |
| 1 Year Change | -23.18% |
| 3 Year Change | 100.31% |
| 5 Year Change | 288.74% |
| Change since IPO | 30,156.22% |
Recent News & Updates
Why The 23% Return On Capital At Sartorius (ETR:SRT) Should Have Your Attention
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
If You Like EPS Growth Then Check Out Sartorius (ETR:SRT) Before It's Too Late
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Here's Why Sartorius (ETR:SRT) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Shareholder Returns
| SRT | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 6.5% | 7.6% | -0.5% |
| 1Y | -23.2% | -16.3% | -21.1% |
Return vs Industry: SRT underperformed the German Medical Equipment industry which returned -16.3% over the past year.
Return vs Market: SRT underperformed the German Market which returned -21.1% over the past year.
Price Volatility
| SRT volatility | |
|---|---|
| SRT Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.9% |
Stable Share Price: SRT is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SRT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 15,051 | Joachim Kreuzburg | https://www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products.
Sartorius Fundamentals Summary
| SRT fundamental statistics | |
|---|---|
| Market Cap | €22.51b |
| Earnings (TTM) | €434.19m |
| Revenue (TTM) | €3.68b |
51.4x
P/E Ratio6.1x
P/S RatioIs SRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT income statement (TTM) | |
|---|---|
| Revenue | €3.68b |
| Cost of Revenue | €1.72b |
| Gross Profit | €1.96b |
| Other Expenses | €1.53b |
| Earnings | €434.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 21, 2022
| Earnings per share (EPS) | 6.35 |
| Gross Margin | 53.20% |
| Net Profit Margin | 11.79% |
| Debt/Equity Ratio | 98.7% |
How did SRT perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield20%
Payout RatioValuation
Is SRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRT?
Other financial metrics that can be useful for relative valuation.
| What is SRT's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €22.51b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.7x |
| Enterprise Value/EBITDA | 20.7x |
| PEG Ratio | 6.1x |
Price to Earnings Ratio vs Peers
How does SRT's PE Ratio compare to its peers?
| SRT PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33x | ||
SHL Siemens Healthineers | 28.2x | 12.8% | €53.5b |
AFX Carl Zeiss Meditec | 38.7x | 9.2% | €10.2b |
SBS Stratec | 27.4x | 13.3% | €1.1b |
DRW3 Drägerwerk KGaA | 37.5x | 43.5% | €863.7m |
SRT Sartorius | 51.4x | 8.4% | €22.5b |
Price-To-Earnings vs Peers: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the peer average (33x).
Price to Earnings Ratio vs Industry
How does SRT's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the German Medical Equipment industry average (28.3x)
Price to Earnings Ratio vs Fair Ratio
What is SRT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 51.4x |
| Fair PE Ratio | 28.7x |
Price-To-Earnings vs Fair Ratio: SRT is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).
Share Price vs Fair Value
What is the Fair Price of SRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRT (€326.5) is trading above our estimate of fair value (€229.27)
Significantly Below Fair Value: SRT is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: SRT is poor value based on its PEG Ratio (6.1x)
Discover undervalued companies
Future Growth
How is Sartorius forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
8.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRT's forecast earnings growth (8.4% per year) is above the savings rate (-0.05%).
Earnings vs Market: SRT's earnings (8.4% per year) are forecast to grow faster than the German market (8.3% per year).
High Growth Earnings: SRT's earnings are forecast to grow, but not significantly.
Revenue vs Market: SRT's revenue (9.6% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: SRT's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRT's Return on Equity is forecast to be high in 3 years time (25%)
Discover growth companies
Past Performance
How has Sartorius performed over the past 5 years?
Past Performance Score
5/6Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
29.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRT has a large one-off loss of €253.0M impacting its March 31 2022 financial results.
Growing Profit Margin: SRT's current net profit margins (11.8%) are higher than last year (10%).
Past Earnings Growth Analysis
Earnings Trend: SRT's earnings have grown significantly by 29% per year over the past 5 years.
Accelerating Growth: SRT's earnings growth over the past year (65.5%) exceeds its 5-year average (29% per year).
Earnings vs Industry: SRT earnings growth over the past year (65.5%) exceeded the Medical Equipment industry 1.3%.
Return on Equity
High ROE: SRT's Return on Equity (29.4%) is considered high.
Discover strong past performing companies
Financial Health
How is Sartorius's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: SRT's short term assets (€1.9B) exceed its short term liabilities (€1.5B).
Long Term Liabilities: SRT's short term assets (€1.9B) do not cover its long term liabilities (€2.4B).
Debt to Equity History and Analysis
Debt Level: SRT's net debt to equity ratio (86.2%) is considered high.
Reducing Debt: SRT's debt to equity ratio has reduced from 117.7% to 98.7% over the past 5 years.
Debt Coverage: SRT's debt is well covered by operating cash flow (42.6%).
Interest Coverage: SRT earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Sartorius's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.38%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SRT's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.45%).
High Dividend: SRT's dividend (0.38%) is low compared to the top 25% of dividend payers in the German market (4.5%).
Stability and Growth of Payments
Stable Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: SRT is not paying a notable dividend for the German market.
Cash Payout to Shareholders
Cash Flow Coverage: SRT is not paying a notable dividend for the German market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
Joachim Kreuzburg (56 yo)
19.58yrs
Tenure
€2,585,000
Compensation
Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH.Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...
CEO Compensation Analysis
Compensation vs Market: Joachim's total compensation ($USD2.72M) is below average for companies of similar size in the German market ($USD5.66M).
Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: SRT's management team is seasoned and experienced (5.3 years average tenure).
Board Members
Experienced Board: SRT's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sartorius Aktiengesellschaft's employee growth, exchange listings and data sources
Key Information
- Name: Sartorius Aktiengesellschaft
- Ticker: SRT
- Exchange: XTRA
- Founded: 1870
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €22.505b
- Shares outstanding: 68.42m
- Website: https://www.sartorius.com
Number of Employees
Location
- Sartorius Aktiengesellschaft
- Otto-Brenner-Strasse 20
- Göttingen
- Lower Saxony
- 37079
- Germany
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/28 00:00 |
| End of Day Share Price | 2022/06/28 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.